BIOTRONIK Blog

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, is pleased to announce today the approval of two new indications for the Orsiro ® Mission Drug-Eluting Stent (DES): One-month Dual Antiplatelet Therapy (DAPT) for High Bleeding Risk (HBR) Patients: Allows practitioners to offer personalized, shorter DAPT durations to their patients at high risk of bleeding events, in accordance with the most recent guidelines. Calcified Lesions Treatment: Allows practitioners to target more complex lesions with moderate or severe calcification. These new indications

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, is pleased to announce the first in-human implantations in BIO|Master.CSP study examining the use of the investigational BIOTRONIK next-generation Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Left bundle branch area pacing is an emerging technique providing a more physiologic activation of cardiac tissue in patients needing ventricular pacing support. This pacing site may also help avoid the detrimental effects of traditional right ventricular pacing. 1, 2 Building on the

BIOTRONIK has enrolled the first patients in its BIO-OSCAR FIRST trial, a study designed to confirm the safety and clinical performance of the Oscar ® Peripheral Multifunctional Catheter for dilation of lesions in the femoral, popliteal and infrapopliteal arteries 1, including both above-the-knee (ATK) and below-the-knee (BTK) lesions. The BIO-OSCAR FIRST trial is a prospective, multicenter, single-arm observational study involving 16 European sites within CE-mark accepting territories. Over the next 12 months, the trial aims to enroll 200 subjects - 100 for ATK and 100 for BTK lesions. This